Clinical trial NCT05798156: Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
Official title: A Prospective Multicenter Phase 2 Study of the Chemotherapy-light Combination of Intravenous Rituximab With the Antibody-drug Conjugate Polatuzumab Vedotin and the Bispecific Antibody Glofitamab in Previously Untreated Aggressive B-cell Lymphoma Patients Above 60 Years of Age Ineligible for a Fully Dosed R-CHOP
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Lymphoma, Large B-Cell, Diffuse
Lead sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Sponsor class: OTHER
Collaborators: name: Charite University, Berlin, Germany
name: University of Salzburg
name: Arbeitsgemeinschaft medikamentoese Tumortherapie
name: Roche Pharma AG
name: Zentrum für Klinische Studien Leipzig
name: Hoffmann-La Roche
First posted: 2023-04-04
Enrollment: 125
Sex: ALL
Minimum age (years): 61
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In the present trial the chemotherapy- light treatment concept R-Pola-Glo will be evaluated that combines the anti-CD20 antibody rituximab (R) with the ADC polatuzumab vedotin (Pola) and the (BiMabs) glofitamab (Glo) in elderly and/or medical unfit and previously untreated patients with aggressive B-cell lymphoma. The outcome and feasibility data obtained here will be used for further clinical development of this new chemolight triple combination.


Eligibility criteria: Inclusion Criteria:

1. Patient has provided written informed consent and is able and willing to comply with the study protocol and protocol mandated treatments according to ICH and local regulations.
2. Patient is above 60 years of age
3. Patient is not eligible for a fully dosed R-CHOP
4. Patient has histologically confirmed aggressive B-cell lymphoma.
5. Patient has at least one measurable FDG PET-positive lymphoma manifestation; defined as lesional maximum FDG uptake higher than the maximum FDG uptake in unaffected liver parenchyma as measured in a reference volume-of-interest with \>10 mL
6. Baseline biopsy material is available for central review.
7. Female patients considered as women of childbearing potential (WOCBP, see section 5.2.7 for definition) and male patients with female partners considered as WOCBP must:

   1. agree to either remain completely abstinent (refrain from heterosexual intercourse) or to use at least one effective contraceptive methods that results in a failure rate of \< 1% per year
   2. refrain from donating ova (female patients) or donating sperm (male patients)
   3. in case of male patients with pregnant female partners, remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures such as a condom to avoid exposing the embryo.
8. Patient did not receive any prior systemic lymphoma therapy.
9. Patient has an ECOG performance status of ≤ 2.
10. Patient has with treatment a life expectancy (in the opinion of the investigator) of at least 12 weeks.
11. Patient has adequate liver function
12. Patient as adequate hematological function
13. Patient has adequate renal function
14. Patients has negative serologic and/or polymerase chain reaction (PCR) test results for:

    * Acute or chronic hepatitis B (HBV) infection.
    * Hepatis C virus (HCV) and human immunodeficiency virus (HIV)
15. Patient has no active SARS-CoV-2 infection.

Exclusion Criteria:

Medical conditions:

1. Patient with chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL) (including CD20+ ALL), lymphoblastic lymphoma, Richter's transformation, Burkitt lymphoma.
2. Patient ≤ 60 years
3. Patient with known active infection, or reactivation of a latent infection, whether bacterial (e.g., tuberculosis), viral (including, but not limited to severe pneumonia, COVID-19, Epstein-Barr virus \[EBV\], cytomegalovirus \[CMV\], hepatitis B, hepatitis C, and HIV\], fungal, mycobacterial, or other pathogens (excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with IV antibiotics (for IV antibiotics this pertains to completion of last course of antibiotic treatment) within 4 weeks prior to study enrollment.
4. Patient with current \> Grade 1 peripheral neuropathy.
5. Patient with history of confirmed progressive multifocal leukoencephalopathy (PML).
6. Patient with history of leptomeningeal disease.
7. Patient with current or history of CNS lymphoma.
8. Patient with current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease with exceptions.
9. Patient with another invasive malignancy in the last 2 years (with the exception of basal cell carcinoma and tumors deemed by the Investigator to be of low likelihood for recurrence), with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate 90%), such as adequately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer.
10. Patient with significant or extensive history of cardiovascular disease (such as New York Heart Association (NYHA) Class ≥ II cardiac disease, congestive heart failure, myocardial infarction or cerebrovascular accident within the past 3 months, unstable arrhythmias, or unstable angina or history of multiple cardiovascular events) or significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
11. Patient with active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis (see addendum for a more comprehensive list of autoimmune diseases and immune deficiencies), with exceptions.
12. Patient with uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently).
13. Patient with history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic.

    Prior/Concomitant Therapy:
14. Patient received treatment with any other standard anti-cancer radiotherapy/chemotherapy including investigational therapy (defined as treatment for which there is currently no regulatory authority approved indication) within 4 weeks or five times the elimination half-life of the product, whichever is longer, prior to study enrollment.
15. Patient with prior solid organ transplantation.
16. Patient with prior allogeneic stem cell transplantation.
17. Patient with prior treatment with targeted therapies (e.g., tyrosine kinase inhibitors, systemic immunotherapeutic/immunostimulating agents, including, but not limited to, CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, radio-immunoconjugates, antibody-drug conjugates, immune/cytokines, and monoclonal antibodies) within 4 weeks or five half-lives of the drug, whichever is shorter, prior to study enrollment.
18. Patient with toxicities from prior anti-cancer therapy including immunotherapy that did not resolve to ≤ Grade 1 except for alopecia, endocrinopathy managed with replacement therapy and stable vitiligo.
19. Patient with any history of immune related ≥ Grade 3 AE except for endocrinopathy managed with replacement therapy.
20. Patient with ongoing corticosteroid use 25 mg/day of prednisone or equivalent within 4 weeks prior and during study treatment.
21. Patient with treatment with systemic immunosuppressive medication (including, but not limited to, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with exceptions.
22. Patient who received administration of a live, attenuated vaccine within 4 weeks prior to study enrollment infusion or anticipation that such a live, attenuated vaccine will be required during the study or within 5 months after the last dose of study treatment.

    Other Exclusions:
23. Patient with history of illicit drug or alcohol abuse within 12 months prior to screening, in the Investigator's judgment.
24. Patient with history of severe allergic anaphylactic reactions to chimeric or humanized monoclonal antibodies or recombinant antibody-related fusion proteins.
25. Patient with known hypersensitivity to Chinese hamster ovary (CHO) cell products or to any component of the rituximab, obinutuzumab, polatuzumab vedotin and/or glofitamab formulation and/or to the contrast agents used in the study.
26. Female patient is pregnant or breast feeding. Female patients of childbearing potential must have a negative serum pregnancy test result within 7 days prior to initiation of study treatment.
27. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities.
28. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts.
29. Patients who are dependent on the sponsor, the investigator or the trial site.

Primary outcomes:
measure: 1 year progression-free survival (PFS) rate of the first 80 patients
timeFrame: 12 months
Secondary outcomes:
measure: Event-free survival (EFS)
timeFrame: 54 months
measure: Overall survival (OS)
timeFrame: 54 months
measure: Response rate at different timepoints
timeFrame: 6 weeks, 18 weeks, 36 weeks
measure: Relapse rate
timeFrame: 54 months
measure: Conversion rate of PR to CR
timeFrame: 54 months
measure: Duration of response (DoR)
timeFrame: 54 months
measure: Rate and type of adverse events (AEs) and serious adverse events (SAEs)
timeFrame: 54 months
measure: Rate of secondary malignancies
timeFrame: 54 months
measure: Treatment-related death rate
timeFrame: 54 months
measure: Protocol adherence
timeFrame: 54 months
measure: Patient-reported outcomes for quality of life (QoL): EORTC QLQ-C30
timeFrame: 54 months
measure: Patient-reported outcomes for quality of life (QoL): FACT-Lym
timeFrame: 54 months
Other outcomes:
measure: Rate of minimal residual disease (MRD)-negative patients after end of target phase and at end of treatment
timeFrame: 54 months
measure: Duration of molecular remission for MRD negative patients
timeFrame: 54 months
measure: Outpatient setting w/o hospitalization
timeFrame: During Cycle 1-6
measure: Outpatient setting with hospitalization
timeFrame: During Cycle 1-6
measure: Cycles safely administered in outpatient setting per patient.
timeFrame: During Cycle 1-12
Locations:
city: Innsbruck
country: Austria
facility: Uniklinik Innsbruck
city: Linz
country: Austria
facility: Kepler Universitätsklinikum
city: Linz
country: Austria
facility: Ordensklinikum Linz - Barmherzige Schwestern
city: Linz
country: Austria
facility: Ordensklinikum Linz - Elisabethinen
city: Salzburg
country: Austria
facility: Landeskrankenhaus Salzburg Universitätsklinikum der Paracelsus Medizinischen Privatuniversität
city: St. Pölten
country: Austria
facility: Univ. Klinikum St. Pölten
city: Wien
country: Austria
facility: AKH Meduni Wien
city: Wien
country: Austria
facility: Hanusch Krankenhaus
city: Magdeburg
country: Germany
facility: Universitätsklinikum Magdeburg
state: Sachsen-Anhalt
city: Berlin
country: Germany
facility: Charité - Universitätsmedizin Berlin
city: Berlin
country: Germany
facility: HELIOS Klinikum Berlin-Buch
city: Bochum
country: Germany
facility: Medizinisches Universitätsklinikum Knappschaftskrankenhaus Bochum
city: Chemnitz
country: Germany
facility: Klinikum Chemnitz
city: Düsseldorf
country: Germany
facility: Uniklinikum Düsseldorf
city: Erlangen
country: Germany
facility: Universitätsklinikum Erlangen
city: Essen
country: Germany
facility: Ev. Klinikum Essen-Mitte
city: Essen
country: Germany
facility: Westdeutsches Tumorzentrum Essen
city: Göttingen
country: Germany
facility: Universitätsmedizin Göttingen
city: Halle
country: Germany
facility: Universitätsklinikum Halle
city: Jena
country: Germany
facility: University Hospital Jena
city: Kiel
country: Germany
facility: Universitätsklinikum Schleswig-Holstein Campus Kiel
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig
city: Leverkusen
country: Germany
facility: Klinikum Leverkusen
city: Ludwigshafen
country: Germany
facility: Klinikum Ludwigshafen
city: München
country: Germany
facility: TU München (rechts des Isar)
city: Münster
country: Germany
facility: Unversitätsklinikum Münster
city: Offenburg
country: Germany
facility: Ortenauklinikum Offenburg-Kehl
city: Regensburg
country: Germany
facility: Universitätsklinikum Regensburg
city: Reutlingen
country: Germany
facility: Kreiskliniken Reutlingen
city: Würzburg
country: Germany
facility: Universitätsklinikum Würzburg
Study officials:
affiliation: Institut fuer Klinische Krebsforschung IKF GmbH
name: Salah-Eddin Al-Batran, Prof. Dr.
role: STUDY_CHAIR
References: